IL-DISCOVER-FINANCIAL
18.1.2023 11:01:38 CET | Business Wire | Press release
Discover® Global Network, the payments brand of Discover®, has launched Tap and Pay solutions with transit agencies and local acquiring partners such as EMT Madrid, Metro de Seville and GetNet in Spain, Mennica in Poland and New Taipei Metro in Taiwan. Riders may now use their Discover, Diners Club International® and network alliance partner cards to make contactless payments at these transit agencies in top international destinations.
As commuting continues to change and riders expect flexibility in how they pay, transit agencies are migrating to contactless payments at a faster pace than anything seen in the past decade. As of February 2022, 53 percent of transit transactions are contactless, up from 14 percent in August of 2020. Globally, 150 large cities are looking to adopt contactless payments for transit systems1.
“The Discover® Transit Solution gives riders the flexibility to pay how they want and provides a seamless customer experience,” said Emily Foshee, vice president of core network products and delivery at Discover. “Accepting contactless payments from cardholders in the Discover Global Network can help transit companies drive volume, lower operating costs and decrease cost of fare collection.”
“We’re excited to enable acceptance growth with transit companies like EMT Madrid and Metro de Seville in Spain. This ensures Discover® Global Network Cardholders have an enjoyable seamless experience when they visit," says Rubén Justel, CEO at Getnet Europe.
“This solution allows us to offer an improved customer experience and make travel easier and more convenient for our riders,” said Jorge Maroto, managing director at Metro de Sevilla, the Seville underground in Spain.
The Discover® Transit Solution enables acceptance of both traditional and contactless transit payments and offers customizable options including supporting merchant transit fare policies, pass products (credentialing), white labeling, contactless payments, first ride risk share and payment account reference.
Discover has been working with transit partners in the U.S. since 2012 and is enabled on Chicago Transit Authority (CTA), New York Metropolitan Transit Authority (NY MTA), Albany, NY (CDTA) Dallas Area Rapid Transit (DART) and Portland (Tri-Met). The Company also has a robust pipeline of agencies in the U.S. and across the globe that are in the process of migrating to contactless payments, with Discover® Transit Solution launches in Turkey and Qatar coming soon.
Discover Global Network is the fastest growing global payments network2 with more than 280 million cardholders, more than 60 million merchant acceptance locations and 1.8 million ATM and cash access locations. It includes Discover Network, Diners Club International, PULSE® and more than 25 alliance partner networks across the globe.
For more information, visit https://www.discoverglobalnetwork.com/solutions/enable-payments/transit-solutions/.
About Discover
Discover Financial Services (NYSE: DFS) is a digital banking and payment services company with one of the most recognized brands in U.S. financial services. Since its inception in 1986, the company has become one of the largest card issuers in the United States. The company issues the Discover® Card, America's cash rewards pioneer, and offers private student loans, personal loans, home loans, checking and savings accounts and certificates of deposit through its banking business. It operates the Discover® Global Network comprised of Discover Network, with millions of merchants and cash access locations; PULSE®, one of the nation's leading ATM/debit networks; and Diners Club International®, a global payments network with acceptance around the world. For more information, visit www.discover.com/company.
1. ABI Research Open and Closed Loop EMV Acceptance on Transportation Networks, May 2021
2. Based on signed alliance agreements over the past twelve years with major payment networks within respective countries — Panoramic Research study, conducted 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom